Deutsche Bank Appointed as Depositary Bank for the Sponsored Level I American Depositary Receipt Program of Daiichi Sankyo

NEW YORK--(BUSINESS WIRE)-- Deutsche Bank today announced its appointment as depositary bank for the Level I American Depositary Receipt (ADR) program of Japan-based Daiichi Sankyo Company, Ltd. (Daiichi Sankyo).

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. Daiichi Sankyo does business in nearly 60 countries around the world, with world headquarters in Tokyo, Japan. With net sales of approximately US$11.8 billion in fiscal year 2010 (as of March 31, 2011), Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies. Daiichi Sankyo employs around 30,500 people, who passionately work to achieve the company's goals. In delivering high-quality products, services and processes, precision serves as a cornerstone of the company's philosophy.*

Toshiaki Sai, Corporate Officer, Vice President of Corporate Communications, Daiichi Sankyo, said, "We are very pleased to start our ADR program and look forward to communicating with further investors in the U.S.”

Akbar Poonawala, Head of Global Equity Services at Deutsche Bank said, “We are delighted to be appointed as the depositary bank for Daiichi Sankyo’s ADR program. We look forward to working with Daiichi Sankyo in the management of its program and are pleased to expand our portfolio of Japanese ADR issuers.”

*Source: Daiichi Sankyo (November 2011)

About Deutsche Bank

Deutsche Bank is a leading global investment bank with a strong private clients franchise. Its businesses are mutually reinforcing. A leader in Germany and Europe, the bank is continuously growing in North America, Asia and key emerging markets. With more than 100,000 employees in 73 countries, Deutsche Bank competes to be the leading global provider of financial solutions, creating lasting value for its clients, shareholders, people and the communities in which it operates.

www.db.com

Trust & Securities Services

Deutsche Bank’s Trust & Securities Services business, part of Global Transaction Banking, is one of the leading providers of trustee, agent, depositary, registrar, SPV management and related services for a wide range of financial structures and transactions. It is a leading depositary for American and Global Depositary Receipts, providing value-added services to companies raising capital in international markets or listing on the New York, NASDAQ, London, Luxembourg, Singapore or NASDAQ Dubai stock exchanges by means of depositary receipts. It also offers both mutual and alternative fund administration and provides securities custody, clearing and agency lending services from a global network spanning more than 30 markets. Additional details are available on www.adr.db.com or www.tss.db.com.

This announcement appears as a matter of record only. This announcement has been approved and/or communicated by Deutsche Bank AG New York.

The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Services Authority. This notice has been approved and/or communicated by Deutsche Bank AG London. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2011 Deutsche Bank AG. All rights reserved.



CONTACT:

Deutsche Bank AG
Press & Media Relations
John Gallagher, +1 212 250 4516
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  New York  Japan

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Banking  Finance

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.